Nearly 60% of US adults qualify for at least one novel cardiovascular, kidney, or metabolic drug — most often a GLP-1 receptor agonist — with many eligible for more than one class of drugs.

Fish treated with SGLT2 inhibitors maintained healthier kidneys as they aged. Their kidneys preserved denser networks of capillaries, retained a stronger filtration barrier, and showed more stable ...

Topline results from the REIMAGINE 2 trial involving 2,728 adults with type 2 diabetes inadequately controlled on metformin ...

Arch Biopartners Inc. ('Arch” or the 'Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team ...

A new study suggests that a group of drugs commonly used to treat diabetes may do exactly that. The research, recently published in the journal Kidney International, shows that medications known as ...

While the drug also previously succeeded in two obesity studies, it fell short of expectations at the time.

Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.

A group of medications often used to treat diabetes may also help protect aging kidneys, according to a new study.

Heart failure management includes the four pillars (quad therapy) in HFrEF and HFpEF, plus advances in heart transplantation ...

Results of a phase 2 randomized controlled trial demonstrate that a podocyte-targeted therapy may be a therapeutic strategy for treating primary focal segmental glomerulosclerosis ...

A machine learning model incorporating functional assessments predicts one-year mortality in older patients with HF and improves risk stratification beyond established scores. Functional status at ...